BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2025 4:21:35 AM | Browse: 18 | Download: 42
 |
Received |
|
2024-10-23 01:36 |
|
Peer-Review Started |
|
2024-10-23 01:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-04 00:42 |
|
Revised |
|
2025-01-16 01:02 |
|
Second Decision |
|
2025-02-08 02:32 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-08 10:08 |
|
Articles in Press |
|
2025-02-08 10:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-11 00:31 |
|
Publish the Manuscript Online |
|
2025-02-26 04:21 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hai-Nan Ma, Kai-Sen Cao, Yan-Miao Liu, Cheng Chen, Hang Zhang and Fu-Shan Tang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com |
| Key Words |
Tenofovir amibufenamide; Tenofovir alafenamide; Chronic hepatitis B; Antiviral efficacy; Safety profile; Hyperlipidemia |
| Core Tip |
Tenofovir amibufenamide demonstrates comparable efficacy to tenofovir alafenamide in the treatment of chronic hepatitis B. Tenofovir amibufenamide offers improved safety, particularly in lipid management, with minimal effects on bone and renal health. Its favorable metabolic profile makes it an attractive option for patients with hyperlipidemia, providing antiviral efficacy without compromising metabolic health. Large-scale, multicenter studies are essential to validate long-term outcomes and its suitability for special patient populations. |
| Publish Date |
2025-02-26 04:21 |
| Citation |
<p>Ma HN, Cao KS, Liu YM, Chen C, Zhang H, Tang FS. Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. <i>World J Gastroenterol</i> 2025; 31(10): 102580</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i10/102580.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i10.102580 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
